Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients

A simple and sensitive method for the simultaneous detection of imatinib mesylate and its active metabolite, N-desmethylimatinib, in human serum samples was developed. Separation was successfully achieved using an Agilent® ZORBAX Eclipse plus Cis reversed phase column (50 x 2.1 mm, i.d.; 1.8 pm) u...

Full description

Saved in:
Bibliographic Details
Main Author: Liong, Tan Ka
Format: Thesis
Language:English
Published: 2013
Subjects:
Online Access:http://eprints.usm.my/60900/1/TAN%20KA%20LIONG%20-%20e.pdf
http://eprints.usm.my/60900/
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Sains Malaysia
Language: English
id my.usm.eprints.60900
record_format eprints
spelling my.usm.eprints.60900 http://eprints.usm.my/60900/ Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients Liong, Tan Ka R Medicine RC254-282 Neoplasms. Tumors. Oncology (including Cancer) RC648-665 Diseases of the endocrine glands. Clinical endocrinology A simple and sensitive method for the simultaneous detection of imatinib mesylate and its active metabolite, N-desmethylimatinib, in human serum samples was developed. Separation was successfully achieved using an Agilent® ZORBAX Eclipse plus Cis reversed phase column (50 x 2.1 mm, i.d.; 1.8 pm) under isocratic mobile phase conditions consisting of acetonitrile: 0.02 M potassium dihydrogen phosphate with 0.2% triethylamine added at pH 3 (25:75, v/v) and ultra-violet detection at 235 nm. Extraction of the target compounds was completed by a protein precipitation method using 100% cold acetonitrile. Good linearities (r2 > 0.99) for Ndesmethyhmafaob and imatinib mesylate were achieved for the concentration ranges of 50-360 ng/mL and 50-1800 ng/mL, respectively. The detection limits were 20 ng/mL and 10 ng/mL for N-desmethylimatinib and imatinib mesylate, respectively. The intra- and inter-day precisions were less than 1% while the percentage recoveries were more than 95%. The method was successfully applied to calculate the pharmacokinetic parameters of chronic myeloid leukemia patients receiving imatinib. For imatinib, mean Vd was 113.32 ± 43.52 L, CL was 5.012 ± 0.028 L and AUC was 62953.33 ± 9791.38 ng.h.L’1. For N-desmethylimatirab, mean Vd was 415.27 ± 228.72 L, CL was 4.84 ± 3.85 L and AUC was 5585.15 ± 2950.42 ng.h.L’1. The method is suitable to be routinely applied for determination of ZV-ctesTnetAyZimatinib and imatinib mesylate in serum. 2013-03 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/60900/1/TAN%20KA%20LIONG%20-%20e.pdf Liong, Tan Ka (2013) Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients. Masters thesis, Universiti Sains Malaysia.
institution Universiti Sains Malaysia
building Hamzah Sendut Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Sains Malaysia
content_source USM Institutional Repository
url_provider http://eprints.usm.my/
language English
topic R Medicine
RC254-282 Neoplasms. Tumors. Oncology (including Cancer)
RC648-665 Diseases of the endocrine glands. Clinical endocrinology
spellingShingle R Medicine
RC254-282 Neoplasms. Tumors. Oncology (including Cancer)
RC648-665 Diseases of the endocrine glands. Clinical endocrinology
Liong, Tan Ka
Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
description A simple and sensitive method for the simultaneous detection of imatinib mesylate and its active metabolite, N-desmethylimatinib, in human serum samples was developed. Separation was successfully achieved using an Agilent® ZORBAX Eclipse plus Cis reversed phase column (50 x 2.1 mm, i.d.; 1.8 pm) under isocratic mobile phase conditions consisting of acetonitrile: 0.02 M potassium dihydrogen phosphate with 0.2% triethylamine added at pH 3 (25:75, v/v) and ultra-violet detection at 235 nm. Extraction of the target compounds was completed by a protein precipitation method using 100% cold acetonitrile. Good linearities (r2 > 0.99) for Ndesmethyhmafaob and imatinib mesylate were achieved for the concentration ranges of 50-360 ng/mL and 50-1800 ng/mL, respectively. The detection limits were 20 ng/mL and 10 ng/mL for N-desmethylimatinib and imatinib mesylate, respectively. The intra- and inter-day precisions were less than 1% while the percentage recoveries were more than 95%. The method was successfully applied to calculate the pharmacokinetic parameters of chronic myeloid leukemia patients receiving imatinib. For imatinib, mean Vd was 113.32 ± 43.52 L, CL was 5.012 ± 0.028 L and AUC was 62953.33 ± 9791.38 ng.h.L’1. For N-desmethylimatirab, mean Vd was 415.27 ± 228.72 L, CL was 4.84 ± 3.85 L and AUC was 5585.15 ± 2950.42 ng.h.L’1. The method is suitable to be routinely applied for determination of ZV-ctesTnetAyZimatinib and imatinib mesylate in serum.
format Thesis
author Liong, Tan Ka
author_facet Liong, Tan Ka
author_sort Liong, Tan Ka
title Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
title_short Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
title_full Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
title_fullStr Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
title_full_unstemmed Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
title_sort ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
publishDate 2013
url http://eprints.usm.my/60900/1/TAN%20KA%20LIONG%20-%20e.pdf
http://eprints.usm.my/60900/
_version_ 1816131389003661312